Biotech

All Articles

Arrowhead fires off phase 3 information in unusual metabolic ailment in advance of market clash with Ionis

.Arrowhead Pharmaceuticals has actually shown its own give before a possible face-off with Ionis, pu...

Pfizer, Valneva show lyme illness try successful for second enhancer

.Pfizer and Valneva might have concerning pair of even more years to stand by prior to they produce ...

Fierce Biotech Managing Editor Ayla Ellison Chats Shop with Michelle Benz on the Future of Biotech.

.Let's dive into a conversation with Ayla Ellison, Tough Biotech Editor-in-Chief and Michelle Benz a...

New records demonstrate how Bayer's asundexian failed to stop movements

.Bayer put on hold the phase 3 test for its own aspect XIa prevention asundexian late in 2015 after ...

Sanofi's tolebrutinib stops working 2 of 3 late-stage MS tests

.Sanofi is still set on taking its a number of sclerosis (MS) med tolebrutinib to the FDA, executive...

Galapagos' stockpile as fund presents intent to shape its development

.Galapagos is actually happening under added tension from investors. Having actually constructed a 9...

Cell- centered Sana gathers first CSO-- Chutes &amp Ladders

.Invite to this week's Chutes &amp Ladders, our summary of notable management hirings, firings and a...

Allist pays off Jacobio $21M, landing job in Chinese KRAS race

.Shanghai Allist Pharmaceuticals has acquired itself a starring role in China's KRAS market, paying ...

ReNeuron leaving behind goal substitution after skipping fundraising target

.ReNeuron has joined the long checklist of biotechs to leave behind Greater london's purpose securit...

MBX files for IPO to take opposition to Ascendis in to phase 3

.MBX Biosciences has contributed to the recent spurt of IPO filings. The biotech, which filed its ow...